ofloxacin has been researched along with Prostatic Hyperplasia in 10 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This multicenter clinical study was designed to compare FRPM 300 mg 3 times daily to Levofloxacin (LVFX), which is the standard treatment for patients with UTI, 100 mg 3 times daily for 7 days in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy." | 9.10 | [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy]. ( Fujimoto, N; Iihara, K; Inatomi, H; Kobayashi, T; Matsumoto, T; Muratani, T; Nishimura, T; Takahashi, K; Yamada, Y, 2002) |
| "The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l)." | 7.67 | [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. ( Adam, D; Bartosik-Wich, B; Naber, KG; Wittenberger, R, 1986) |
| " This multicenter clinical study was designed to compare FRPM 300 mg 3 times daily to Levofloxacin (LVFX), which is the standard treatment for patients with UTI, 100 mg 3 times daily for 7 days in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy." | 5.10 | [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy]. ( Fujimoto, N; Iihara, K; Inatomi, H; Kobayashi, T; Matsumoto, T; Muratani, T; Nishimura, T; Takahashi, K; Yamada, Y, 2002) |
| "The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l)." | 3.67 | [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. ( Adam, D; Bartosik-Wich, B; Naber, KG; Wittenberger, R, 1986) |
| "The present study was undertaken to evaluate the clinical efficacy of long-term administration of ofloxacin (OFLX) to the patients following transurethral resection of the prostate." | 2.67 | [Study of the long-term administration of ofloxacin to the patients following transurethral resection of the prostate]. ( Hasuda, A; Morita, M; Suzuki, K, 1991) |
| "Ten patients with clinical symptoms of benign prostatic hyperplasia undergoing TUR-P received 200 mg of both drugs per os simultaneously 2 hours before surgery." | 1.31 | Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate. ( Chen, J; Chen, RR; Huang, HS, 2001) |
| "Ofloxacin has the advantage against ciprofloxacin of exceeding the MICs for Staphylococcus and Chlamydia." | 1.30 | A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. ( Cheng, C; Foo, KT; Li, MK; Png, JC; Rekhraj, IR; Tan, E, 1997) |
| "Ofloxacin was administered orally at a dose of 200 mg several hours before subcapsular prostatectomy." | 1.29 | [Ofloxacin concentration in prostatic tissue]. ( Imada, N; Kamoi, K; Kawauchi, A; Kitamori, T; Ohne, T; Terasaki, T; Watanabe, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muratani, T | 1 |
| Iihara, K | 1 |
| Nishimura, T | 1 |
| Inatomi, H | 1 |
| Fujimoto, N | 1 |
| Kobayashi, T | 1 |
| Yamada, Y | 1 |
| Takahashi, K | 1 |
| Matsumoto, T | 1 |
| Tash, K | 1 |
| Kawauchi, A | 1 |
| Kamoi, K | 1 |
| Ohne, T | 1 |
| Imada, N | 1 |
| Kitamori, T | 1 |
| Terasaki, T | 1 |
| Watanabe, H | 1 |
| Png, JC | 1 |
| Tan, E | 1 |
| Foo, KT | 1 |
| Li, MK | 1 |
| Cheng, C | 1 |
| Rekhraj, IR | 1 |
| Chen, J | 1 |
| Chen, RR | 1 |
| Huang, HS | 1 |
| Morita, M | 2 |
| Ito, S | 1 |
| Suzuki, K | 2 |
| Uchibayashi, T | 1 |
| Nagano, K | 1 |
| Shoda, R | 1 |
| Hisazumi, H | 1 |
| Sawaki, M | 1 |
| Yamaguchi, K | 1 |
| Kawaguchi, K | 1 |
| Komatsu, K | 1 |
| Kobashi, K | 1 |
| Koizumi, H | 1 |
| Hasuda, A | 1 |
| Naber, KG | 1 |
| Adam, D | 1 |
| Wittenberger, R | 1 |
| Bartosik-Wich, B | 1 |
| Asakawa, M | 1 |
| Yasumoto, R | 1 |
2 trials available for ofloxacin and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; b | 2002 |
[Study of the long-term administration of ofloxacin to the patients following transurethral resection of the prostate].
Topics: Aged; Drug Administration Schedule; Drug Evaluation; Humans; Male; Middle Aged; Ofloxacin; Postopera | 1991 |
8 other studies available for ofloxacin and Prostatic Hyperplasia
| Article | Year |
|---|---|
Rahnella aquatilis bacteremia from a suspected urinary source.
Topics: Aged; Anti-Bacterial Agents; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Lev | 2005 |
[Ofloxacin concentration in prostatic tissue].
Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Ofloxacin; Permeability; Prostate; Prostatic Hyp | 1993 |
A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion.
Topics: Administration, Oral; Anti-Infective Agents; Anti-Infective Agents, Urinary; Chromatography, High Pr | 1997 |
Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
Topics: Aged; Anti-Infective Agents; Humans; Male; Middle Aged; Norfloxacin; Ofloxacin; Postoperative Compli | 2001 |
[Clinical evaluation of oral ofloxacin in 3-day therapy for transurethral resection of the prostate].
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Ag | 1992 |
[Diffusion of ofloxacin (OFLX) into prostatic tissue in patients with benign prostatic hypertrophy].
Topics: Administration, Oral; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Ofloxacin; Prostate; Prost | 1990 |
[In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
Topics: Aged; Anti-Infective Agents, Urinary; Bacteria; Cross Infection; Dose-Response Relationship, Drug; F | 1986 |
Ofloxacin concentration in human benign prostatic tissue after oral administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Humans; Male; Ofloxacin; Prostate; Prostatic Hyperpla | 1988 |